Sun Sep 15 15:22:53 UTC 2024: ## Federated Hermes Boosts Stake in MoonLake Immunotherapeutics

**Zug, Switzerland – September 15, 2024** – Federated Hermes Inc., a prominent investment firm, has increased its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, by 2.6% during the second quarter, according to a recent SEC filing. This move comes as several other institutional investors have also adjusted their positions in MLTX, with some increasing their stakes and others taking new positions.

Federated Hermes now owns 1,128,428 shares of MoonLake Immunotherapeutics, representing approximately 1.77% of the company’s stock and a value of $49,617,000. This strategic move signals confidence in the company’s potential, particularly as it develops innovative therapies for inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.

The heightened interest in MoonLake Immunotherapeutics is further reflected in the recent research analyst reports. While some analysts have lowered their ratings, several others have maintained “buy” or “overweight” recommendations, citing the company’s promising pipeline and potential for growth.

MoonLake Immunotherapeutics last reported earnings on August 7th, missing analysts’ estimates for the quarter. However, despite the recent earnings miss, the company’s long-term prospects are viewed favorably by many analysts, leading to a consensus “Moderate Buy” rating and a consensus target price of $80.45.

Institutional investors currently own 93.85% of MoonLake Immunotherapeutics stock, demonstrating strong confidence in the company’s potential. As the company continues to advance its therapies through clinical trials, investors will be closely watching for progress and potential breakthroughs.

Read More